This review highlights the importance of evaluating the duration of proton pump inhibitor therapy in light of its association with an increased risk of stomach cancer. Long-term use, defined as one year or more, can significantly heighten this risk, emphasizing the need for judicious use of these medications.

In light of recent disruptions, it’s crucial for healthcare systems to reconsider how consolidation impacts patient care and to explore diverse value-based care models that prioritize patient outcomes.

In a recent phase 3 trial, alectinib has shown a notable improvement in both disease-free and CNS disease-free survival in patients with ALK-positive NSCLC, indicating a robust alternative to platinum-based chemotherapy regimens.

This “From the Editor” in the Cleveland Clinic Journal of Medicine offers a nuanced view of corticosteroid therapy, highlighting the balance between their significant therapeutic benefits and the risk of adverse effects in long-term use.

Acquired reactive perforating collagenosis, characterized by pruritic eruptions and systemic associations, often manifests in patients with diabetes or chronic kidney disease, underscoring the necessity for holistic patient assessment in dermatological evaluations.

Managing venous thromboembolism effectively demands a nuanced understanding of updated clinical guidelines, which now differentiate treatment protocols based on specific risk assessments and patient comorbidities.